Erythropoietin accelerates the proliferation of glioma cells via activating Akt pathway.
- Author:
Zi-Li LIU
1
;
Zhao-Hua TANG
;
Gang HUO
;
Fei-Lan CHEN
;
Wen-Tao WANG
;
Wen-Xin ZENG
;
Hong CHEN
;
Xin LI
;
Chen CHEN
Author Information
- Publication Type:Journal Article
- From: Journal of Southern Medical University 2018;38(4):395-401
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine whether erythropoietin (EPO) promotes rapid proliferation of glioma through Akt pathway.
METHODSWe detected the expression of EPO in human glioma tissues using immunohistochemistry. A nude mouse model bearing human glioma U87 cell xenograft was established and given intraperitoneal injection of EPO or saline every other day, and the tumor growth was observed. In the in vitro experiment, U87 cells were treated with PBS (control), EPO, or EPO with Akt inhibitor, and the expression of p-Akt and cyclin D1 was detected using Western blotting; the cell proliferation rate was determined using cell counting kit-8 and clone formation assay, and the cell cycle changes were analyzed with flow cytometry.
RESULTSCompared with low-grade glioma tissues, high-grade glioma tissues exhibited a significantly increased EPO expression (P=0.0002). In the tumor-bearing mice, EPO treatment significantly increased the expression of EPO (P=0.0006) and p-Akt (P=0.0003) in the tumor and obviously increased the tumor volume (P<0.0001) and weight (P=0.0003). In U87 cells cultured in vitro, EPO treatment obviously accelerated the cell proliferation (P=0.020 on day 3 and 0.028 on day 5), promoted clone formation (P=0.0010), and increased proliferation index (P=0.0028); EPO significantly enhanced the protein expression of p-Akt (P=0.0020) and cyclin D1 (P=0.0022). The application of Akt inhibitor significantly suppressed the effect of EPO in enhancing cyclin D1 and p-Akt expression (both P<0.0001) and promoting cell proliferation.
CONCLUSIONEPO can significantly accelerate the proliferation of glioma through Akt pathway.